Literature DB >> 24569952

Heparin-bonded catheters for prolonging the patency of central venous catheters in children.

Prakeshkumar S Shah1, Niketa Shah.   

Abstract

BACKGROUND: Central venous catheters (CVCs) are a mainstay in the management of critically ill children. However, these catheters are associated with mechanical and infectious complications which reduce their life span. Heparin bonding of catheters has shown promise in animal studies and in adults. This is the first update of a review published in 2007.
OBJECTIVES: The primary objective was to determine the effect of heparin-bonded CVCs on the duration of catheter patency in children. Secondary objectives were to determine the effects of heparin-bonded catheters on catheter-related thrombosis, occlusion, blood stream infection and side effects. SEARCH
METHODS: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). The authors searched MEDLINE (1946 to week 3 August 2013). SELECTION CRITERIA: We included randomized and quasi-randomized controlled trials of heparin-bonded catheters versus non-heparin bonded catheters or antibiotic-impregnated catheters that reported on any of the prespecified outcomes, without language restriction. DATA COLLECTION AND ANALYSIS: We assessed the methodological quality of the trials using the information provided in the studies and by contacting authors. We extracted data and estimated the effect size reported as risk ratio (RR), risk difference (RD) or number needed to treat (NNT), as appropriate. MAIN
RESULTS: We included two eligible studies with a total of 287 participants; both had good methodological quality. There was no difference in the duration of catheter patency between heparin-bonded and non-heparin bonded catheters (median duration seven days versus six days) reported in one study. There was no difference in the risk of catheter-related thrombosis (two studies, RR 0.34, 95% CI 0.01 to 7.68; I(2) = 80%; RD -0.06, 95% CI -0.17 to 0.06). Data from one study revealed a statistically significant reduction in the risk of catheter occlusion (RR 0.06, 95% CI 0.00 to 1.07; RD -0.08, 95% CI -0.13 to -0.02; NNT 13, 95% CI 8 to 50), catheter-related blood stream infections (RR 0.06, 95% CI 0.01 to 0.41; RD -0.17, 95% CI -0.25 to -0.10; NNT 6, 95% CI 4 to 10) and catheter colonization (RR 0.21, 95% CI 0.06 to 0.71; RD -0.11, 95% CI -0.19 to -0.04; NNT 9, 95% CI 5 to 25) in the heparin-bonded catheter group. The second study did not report on these outcomes. There was no significant difference in risk of thrombocytopenia after catheter placement (RR 0.73, 95% CI 0.38 to 1.39; RD -0.02, 95% CI -0.10 to 0.07). AUTHORS'
CONCLUSIONS: Two eligible studies on the use of heparin-bonded catheters versus placebo in children were identified. Meta-analysis of the two studies revealed no reduction in catheter-related thrombosis with heparin-bonded catheters. One study reported a reduction in catheter-related blood stream infection and colonization following the use of heparin-bonded catheters. The strength of evidence is low and further well-designed multicenter randomized controlled trials are warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569952     DOI: 10.1002/14651858.CD005983.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

Review 1.  Potential and Limitations of Cochrane Reviews in Pediatric Cardiology: A Systematic Analysis.

Authors:  Martin Poryo; Sara Khosrawikatoli; Hashim Abdul-Khaliq; Sascha Meyer
Journal:  Pediatr Cardiol       Date:  2017-02-27       Impact factor: 1.655

2.  The immobilization of a direct thrombin inhibitor to a polyurethane as a nonthrombogenic surface coating for extracorporeal circulation.

Authors:  Jane Yu; Elizabeth Brisbois; Hitesh Handa; Gail Annich; Mark Meyerhoff; Robert Bartlett; Terry Major
Journal:  J Mater Chem B       Date:  2016-03-01       Impact factor: 6.331

3.  Factors Associated With Continuous Low-Dose Heparin Infusion for Central Venous Catheter Patency in Critically Ill Children Worldwide.

Authors:  Sara-Jane N Onyeama; Sheila J Hanson; Mahua Dasgupta; Raymond G Hoffmann; Edward Vincent S Faustino
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

4.  Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials.

Authors:  Jinrui Liu; Chang'an Wang; Hongfei Zhao; Jinghua Zhang; Jie Ma; Yuanyuan Hou; Hongbin Zou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 5.  Venous Access Devices: Clinical Rounds.

Authors:  Laurl Matey; Dawn Camp-Sorrell
Journal:  Asia Pac J Oncol Nurs       Date:  2016 Oct-Dec

6.  Effect of impregnated central venous catheters on thrombosis in paediatric intensive care: Post-hoc analyses of the CATCH trial.

Authors:  Yue Wu; Caroline Fraser; Ruth Gilbert; Quen Mok
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

7.  In situ regeneration of bioactive coatings enabled by an evolved Staphylococcus aureus sortase A.

Authors:  Hyun Ok Ham; Zheng Qu; Carolyn A Haller; Brent M Dorr; Erbin Dai; Wookhyun Kim; David R Liu; Elliot L Chaikof
Journal:  Nat Commun       Date:  2016-04-13       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.